Our Pipeline of Investigational Therapies

Surface Oncology® is developing multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable a robust immunologic response and enhance outcomes for patients with cancer.

Surface’s pipeline spans compelling areas of discovery and development across four key areas of immune modulators to: activate both macrophages and natural killer cells, inhibit or deplete regulatory T cells and block suppressive cell signaling molecules, including cytokines and metabolites.

Surface Oncology is conducting a study of SRF231 in patients with advanced solid and hematologic cancers. For more information see www.clinicaltrials.gov.

Surface Oncology is conducting a study of SRF231 in patients with advanced solid and hematologic cancers. For more information see www.clinicaltrials.gov.

Posters & Publications

The Surface team is committed to scientific exchange and continual learning, from each other, from our work and from experts around the world, to break through scientific challenges.

SRF388

SRF114

NZV930

SRF231

How We Break Through

Our team is on a mission to deliver transformative outcomes for people with cancer by breaking through the frontiers of immuno-oncology research.

We seek to substantially increase response rates, response quality and durability, and long-term survival through the unique Surface approach to our research.

Engaging Both the Adaptive and Innate Immune Response

Differentiated antibody programs with strong translational hypotheses